Literature DB >> 19144703

Determinants of the establishment of human immunodeficiency virus type 1 latency.

Alexandra Duverger1, Jennifer Jones, Jori May, Frederic Bibollet-Ruche, Frederic A Wagner, Randall Q Cron, Olaf Kutsch.   

Abstract

Recent research has emphasized the notion that human immunodeficiency virus type 1 (HIV-1) latency is controlled by a restrictive histone code at, or DNA methylation of, the integrated viral promoter (long terminal repeat [LTR]). The present concept of HIV-1 latency has essentially been patterned from the principles of cellular gene regulation. Here we introduce an experimental system that allows for the qualitative and quantitative kinetic study of latency establishment and maintenance at the population level. In this system, we find no evidence that HIV-1 latency establishment is the consequence of downregulation of initial active infection followed by the establishment of a restrictive histone code at the viral LTR. Latent infection was established following integration of the virus in the absence of viral gene expression (silent integration) and was a function of the NF-kappaB activation level in the host cell at the time of infection. In the absence of a role for epigenetic regulation, we demonstrate that transcriptional interference, a mechanism that has recently been suggested to add to the stabilization of HIV-1 latency, is the primary mechanism to govern latency maintenance. These findings provide direct experimental evidence that the high number of viral integration events (>90%) found in actively expressed genes of CD4(+) memory T cells from highly active antiretroviral therapy-suppressed patients represent indeed latent infection events and that transcriptional interference may be the primary mechanism to control HIV-1 latency in vivo. HIV-1 latency may thus not be governed by the principles of cellular gene regulation, and therapeutic strategies to deplete the pool of latently HIV-1-infected cells should be reconsidered.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19144703      PMCID: PMC2655589          DOI: 10.1128/JVI.02058-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  62 in total

1.  Generation of HIV latency during thymopoiesis.

Authors:  D G Brooks; S G Kitchen; C M Kitchen; D D Scripture-Adams; J A Zack
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

2.  HIV-1 integration in the human genome favors active genes and local hotspots.

Authors:  Astrid R W Schröder; Paul Shinn; Huaming Chen; Charles Berry; Joseph R Ecker; Frederic Bushman
Journal:  Cell       Date:  2002-08-23       Impact factor: 41.582

3.  Expression profile of MUM1/IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas.

Authors:  A Carbone; A Gloghini; L M Larocca; D Capello; F Pierconti; V Canzonieri; U Tirelli; R Dalla-Favera; G Gaidano
Journal:  Blood       Date:  2001-02-01       Impact factor: 22.113

4.  The human factors YY1 and LSF repress the human immunodeficiency virus type 1 long terminal repeat via recruitment of histone deacetylase 1.

Authors:  J J Coull; F Romerio; J M Sun; J L Volker; K M Galvin; J R Davie; Y Shi; U Hansen; D M Margolis
Journal:  J Virol       Date:  2000-08       Impact factor: 5.103

5.  The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation.

Authors:  A Jordan; P Defechereux; E Verdin
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

6.  Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection.

Authors:  Theodore C Pierson; Yan Zhou; Tara L Kieffer; Christian T Ruff; Christopher Buck; Robert F Siliciano
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

7.  Direct and quantitative single-cell analysis of human immunodeficiency virus type 1 reactivation from latency.

Authors:  Olaf Kutsch; Etty N Benveniste; George M Shaw; David N Levy
Journal:  J Virol       Date:  2002-09       Impact factor: 5.103

8.  High throughput drug screening for human immunodeficiency virus type 1 reactivating compounds.

Authors:  Jennifer Jones; John Rodgers; Marintha Heil; Jori May; Lucile White; Joseph A Maddry; Thomas M Fletcher; George M Shaw; John L Hartman; Olaf Kutsch
Journal:  Assay Drug Dev Technol       Date:  2007-04       Impact factor: 1.738

Review 9.  Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities.

Authors:  S T Butera
Journal:  Antiviral Res       Date:  2000-12       Impact factor: 5.970

10.  Temporal gene regulation during HIV-1 infection of human CD4+ T cells.

Authors:  J Corbeil; D Sheeter; D Genini; S Rought; L Leoni; P Du; M Ferguson; D R Masys; J B Welsh; J L Fink; R Sasik; D Huang; J Drenkow; D D Richman; T Gingeras
Journal:  Genome Res       Date:  2001-07       Impact factor: 9.043

View more
  68 in total

1.  Hit-and-run stimulation: a novel concept to reactivate latent HIV-1 infection without cytokine gene induction.

Authors:  Frank Wolschendorf; Alexandra Duverger; Jennifer Jones; Frederic H Wagner; Jason Huff; William H Benjamin; Michael S Saag; Michael Niederweis; Olaf Kutsch
Journal:  J Virol       Date:  2010-06-10       Impact factor: 5.103

2.  The viral protein Tat can inhibit the establishment of HIV-1 latency.

Authors:  Daniel A Donahue; Björn D Kuhl; Richard D Sloan; Mark A Wainberg
Journal:  J Virol       Date:  2012-01-11       Impact factor: 5.103

3.  Kinase control prevents HIV-1 reactivation in spite of high levels of induced NF-κB activity.

Authors:  Frank Wolschendorf; Alberto Bosque; Takao Shishido; Alexandra Duverger; Jennifer Jones; Vicente Planelles; Olaf Kutsch
Journal:  J Virol       Date:  2012-02-15       Impact factor: 5.103

4.  Establishment of HIV-1 latency in resting CD4+ T cells depends on chemokine-induced changes in the actin cytoskeleton.

Authors:  Paul U Cameron; Suha Saleh; Georgina Sallmann; Ajantha Solomon; Fiona Wightman; Vanessa A Evans; Genevieve Boucher; Elias K Haddad; Rafick-Pierre Sekaly; Andrew N Harman; Jenny L Anderson; Kate L Jones; Johnson Mak; Anthony L Cunningham; Anthony Jaworowski; Sharon R Lewin
Journal:  Proc Natl Acad Sci U S A       Date:  2010-09-13       Impact factor: 11.205

5.  Combinatorial latency reactivation for HIV-1 subtypes and variants.

Authors:  John C Burnett; Kwang-Il Lim; Arash Calafi; John J Rossi; David V Schaffer; Adam P Arkin
Journal:  J Virol       Date:  2010-03-31       Impact factor: 5.103

Review 6.  Studies of HIV-1 latency in an ex vivo model that uses primary central memory T cells.

Authors:  Alberto Bosque; Vicente Planelles
Journal:  Methods       Date:  2010-10-21       Impact factor: 3.608

7.  RNAP II processivity is a limiting step for HIV-1 transcription independent of orientation to and activity of endogenous neighboring promoters.

Authors:  Katarzyna Kaczmarek Michaels; Frank Wolschendorf; Gillian M Schiralli Lester; Malini Natarajan; Olaf Kutsch; Andrew J Henderson
Journal:  Virology       Date:  2015-09-14       Impact factor: 3.616

8.  Stable Phenotypic Changes of the Host T Cells Are Essential to the Long-Term Stability of Latent HIV-1 Infection.

Authors:  Lillian Seu; Steffanie Sabbaj; Alexandra Duverger; Frederic Wagner; Joshua C Anderson; Elizabeth Davies; Frank Wolschendorf; Christopher D Willey; Michael S Saag; Paul Goepfert; Olaf Kutsch
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

9.  Tumor suppressor cylindromatosis (CYLD) controls HIV transcription in an NF-κB-dependent manner.

Authors:  Lara Manganaro; Lars Pache; Tobias Herrmann; John Marlett; Young Hwang; Jeffrey Murry; Lisa Miorin; Adrian T Ting; Renate König; Adolfo García-Sastre; Frederic D Bushman; Sumit K Chanda; John A T Young; Ana Fernandez-Sesma; Viviana Simon
Journal:  J Virol       Date:  2014-04-23       Impact factor: 5.103

10.  CpG methylation controls reactivation of HIV from latency.

Authors:  Jana Blazkova; Katerina Trejbalova; Françoise Gondois-Rey; Philippe Halfon; Patrick Philibert; Allan Guiguen; Eric Verdin; Daniel Olive; Carine Van Lint; Jiri Hejnar; Ivan Hirsch
Journal:  PLoS Pathog       Date:  2009-08-21       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.